Cardiovascular SurgeryCardiovascular Surgery
Setting the Standard and Leading Innovation in Advanced Cardiac Care.
The Cardiovascular Surgery Team at Cheng-Hsin General Hospital is internationally recognized for its dedication to clinical excellence, cutting-edge research, and global collaboration. The team has published numerous high-impact scientific papers in the field of cardiovascular surgery and has received multiple international awards for its contributions.
In addition to outstanding clinical performance, the team regularly organizes academic conferences and professional training programs, sharing its expertise with medical professionals around the world. Cheng-Hsin has also built long-term partnerships with leading medical institutions and experts globally, actively contributing to international academic exchange and the advancement of cardiovascular surgery worldwide.
Cardiovascular Surgery Innovation and Heart Transplant Excellence
The Department of Cardiovascular Surgery at Cheng-Hsin General Hospital comprises a highly skilled team with extensive expertise in both cardiac and vascular procedures. Their use of mechanical circulatory support devices reflects a strong commitment to providing advanced and comprehensive care.
The hospital’s heart transplant program boasts a remarkable record, with over 580 successful surgeries. Notably, 66 patients have survived for more than 20 years post-transplant, and 8 have exceeded 30 years, surpassing survival rates reported by the U.S. Organ Procurement and Transplantation Network (OPTN) and the Scientific Registry of Transplant Recipients (SRTR).
Pioneering Cardiovascular Innovation Through Advanced Technology
The opening of Taiwan’s first hybrid operating room at Cheng-Hsin General Hospital in 2009, along with the development of innovative open and minimally invasive procedures—such as structural heart interventions—demonstrates the department’s strong commitment to medical innovation. The team’s completion of over 1,200 transcatheter aortic valve implantation (TAVI) procedures highlights their leading role in adopting advanced cardiovascular treatments.
In addition, the introduction of extracorporeal pulse therapy offers an effective non-invasive alternative for patients who are not candidates for traditional cardiac catheterization or bypass surgery. This therapy requires only short-term hospitalization and allows patients to quickly return to their normal daily activities.
Delivering Holistic Patient Care Through Multidisciplinary Collaboration
The department collaborates closely with various specialties, including cardiology, metabolism, infection, rehabilitation, general surgery, and plastic surgery, to provide comprehensive care. Additionally, integration of social workers, psychologists, and other professionals ensures holistic patient support addressing physical, emotional, and psychological needs.
National Innovation Award
The recognition of the Cardiovascular Surgery Team of Cheng-Hsin General Hospital for their innovative “VasoRing Connector” for aortic reconstruction surgery is well-deserved.
It’s reassuring that this product has been licensed in Taiwan and the United States, and that it has an exceptional success rate in reducing complications.
This will certainly benefit patients with cardiovascular diseases and improve their quality of life.
Symbol of National Quality (SNQ)
About 15% of middle-aged and elderly patients who receive transcatheter aortic valve replacement (TAVR) have bicuspid aortic valve stenosis. The cause can be attributed to either congenital abnormalities or degenerative changes. The characteristics of bicuspid aortic valve stenosis include asymmetric valve structure, multiple and uneven calcification, and often lead to complications such as rupture of the aortic root structure, coronary artery occlusion, and implanted valve leakage during surgery. Therefore, it was previously excluded as a suitable candidate for TAVR. Although some patients have attempted to undergo transcatheter valve replacement in recent years, it is a highly difficult and complex procedure, challenging for physicians worldwide.
Under the leadership of Superintendent Wei Jeng, the hospital’s heart valve team discovered in 2016 that the success of TAVR for bicuspid aortic valve stenosis depended on the correct selection of the implanted valve size. The valve team further developed the “Wei’s Measurement Method” which precisely selects the valve size preoperatively and optimizes it post-implantation, greatly improving the safety of the surgery, reducing complications, and improving the long-term prognosis. The “Wei’s measurement method” has been validated in over a hundred bicuspid TAVR patients at the hospital, and its results have been published in internationally renowned journals and presented at various international valve conferences in Europe, America, and Asia. Currently, many valve centers in Asia and mainland China routinely use the “Wei’s measurement method” as the standard measurement method for selecting implanted valve size for bicuspid aortic valve stenosis patients, which demonstrates the hospital’s ongoing efforts to innovate and improve in valve treatment.
Mon~ Fri 8am~5pm.
